TQB2102 Injection

DRUG3 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Conditions

Advanced CancerHER2 IHC3+ Advanced Colorectal CancerMetastatic Breast Cancer

Phase 1

Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers

Active, not recruitingNCT05735496

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Advanced Cancer

Start: 2023-03-09End: 2027-07-31Updated: 2025-08-01

Phase 3

Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer

RecruitingNCT07008976

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Metastatic Breast Cancer

Start: 2025-07-07End: 2028-12-31Target: 246Updated: 2025-08-14

A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs

Not yet recruitingNCT07483684

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.HER2 IHC3+ Advanced Colorectal Cancer

Start: 2026-03-01End: 2028-12-01Target: 142Updated: 2026-03-19

Related Papers

Safety and efficacy of TQB2102, a novel bispecific anti-HER2 antibody–drug conjugate, in patients with advanced solid tumors: Preliminary data from the first-in-human phase 1 trial.

Journal of Clinical Oncology2025-05-283 citations